Pain management in children and adolescents with sickle cell disease

American Journal of Hematology

Volumn 86, Issue 1, 2011, Pages 82-84

  Jerrell, Jeanette M ^a   Tripathi, Avnish ^b   Stallworth, James R ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CODEINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; HYDROCODONE; HYDROXYUREA; IBUPROFEN; MIRTAZAPINE; MORPHINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PAROXETINE; PHENYTOIN; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

AGRANULOCYTOSIS; ANEMIA; BLEEDING; BLOOD TRANSFUSION; CHRONIC PAIN; ECCHYMOSIS; EOSINOPHILIA; EPISTAXIS; ERYTHROCYTE APLASIA; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HUMAN; LETTER; LEUKOCYTOSIS; LEUKOPENIA; NEUTROPENIA; PAIN; PANCYTOPENIA; PRIORITY JOURNAL; SICKLE CELL ANEMIA; THROMBOCYTOPENIA; VASOOCCLUSIVE PAIN;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; HUMANS; PAIN;

EID: 78650351845     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21873     Document Type: Letter

References (27)

1. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference Statement: Hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148: 932-938.
2. Howard J, Thomas VJ, Rawle HM. Pain management and quality of life in sickle cell disease. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 347-352.
3. DeBaun MR, Vichinsky E. Hemoglobinopathies. In Kliegman RM, Behrman RE, Jenson HB, Stanton B, editos. Nelson Textbook of Pediatrics, 18th ed. Philadelphia, PA: WB Saunders Elsevier; 2007. Available at Accessed June 17, 2009.
4. Chambliss CR, Heggen J, Copelan DN, Pettignano R. The assessment and management of chronic pain in children. Paediatr Drugs 2002; 4: 737-746.
5. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996; 88: 1960-1964.
6. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial.Pediatric Hydroxyurea Group. Blood 1999; 94: 1550-1554.
7. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: A systematic review for efficacy and toxicity in children. Pediatrics 2008; 122: 1332-1342.
8. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001; 97: 3628-3632.
9. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood 2005; 106: 2269-2275.
10. Hoppe C, Vichinsky E, Quirolo K, et al. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. J Pediatr Hematol Oncol 2000; 22: 330-334.
11. Jackson KC, St. Onge EL. Antidepressant pharmacotherapy: Considerations for the pain clinician. Pain Pract 2003; 3: 135-143.
12. Sharp J, Keefe B. Psychiatry in chronic pain: A review and update. Curr Psychiatr Rep 2005; 7: 213-219.
13. Gallagher RM. Management of neuropathic pain: Translating mechanistic advances and evidence-based research into clinical practice. Clin J Pain 2006; 22: S2-S8.
14. Wolfe GI, Trivedi JR. Painful peripheral neuropathy and its nonsurgical treatment. Muscle Nerve 2004; 30: 3-19.
15. Sullivan MD, Robinson JP. Antidepressant and anticonvulsant medication for chronic pain. Phys Med Rehabil Clin N Am 2006; 17: 381-400.
16. Jann MW, Slade JH. Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy 2007; 27: 1571-1587.
17. Chong MS, Brandner B. Neuropathic agents and pain: New strategies. Biomed Pharmacother 2006; 60: 318-322.
18. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: A synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry 2009; 31: 206-219.
19. Becker M, Axelrod DJ, Oyesanmi O, et al. Hematologic problems in psychosomatic medicine. Psychiatr Clin North Am 2007; 30: 739-759.
20. Hennessy S, Leonard CE, Freeman CP, Deo R, Newcomb C, Kimmel SE, Strom BL, Bilker WB. Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf 2010; 19: 555-562.
21. Chibnik LB, Massarotti EM, Costenbader KH. Identification and validation of lupus nephritis cases using administrative data. Lupus 2010; 19: 741-743.
22. Darbari DS, Minniti CP, Rana S, van den Anker J. Pharmacogenetics of morphine: Potential implications in sickle cell disease. Am J Hematol 2007; 83: 233-236.
23. Lanzkron S, Haywood CJr, Segal JB, Dover GJ. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol 2006; 81: 927-932.
24. Carroll CP, Haywood CJr, Fagan P, Lanzkron S. The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization. Am J Hematol 2009; 84: 666-670.
25. Ballas SK. The cost of health care for patients with sickle cell disease. Am J Hematol 2009; 84: 320-322.
26. Ijaduola GT, Akinyanju OO. Chronic tonsillitis, tonsillectomy and sickle cell crises. J Laryngol Otol 1987; 101: 467-470.
27. Maddern BR, Reed HT, Ohene-Frempong K, Beckerman RC. Obstructive sleep apnea syndrome in sickle cell disease. Ann Otol Rhinol Laryngol 1989; 98: 174-178.